ENTRADA THERAPEUTICS INC
TRDANASDAQTrading Snapshot
- Day Range
- $6.99 – $7.12
- 52-Week Range
- $4.93 – $16.45
- Volume
- $1.91B
- Avg Volume
- $1.55B
- Shares Outstanding
- 38.8M
- Next Earnings
- Sep 28, 2026
Fundamentals Snapshot
- Annual Revenue
- $25M
- Last Q Revenue
- $898,000
- P/E Ratio
- —
- P/S Ratio
- 57.7x
- EPS (TTM)
- $-3.97
- Dividend Yield
- —
Why Investors Own TRDA
- ✓High-growth profile — revenue up +11.0% YoY with expanding US Equity exposure.
- ✓Healthy economics — 38% gross margin and 21% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About ENTRADA THERAPEUTICS INC
Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches. Its foremost product candidate, ENTR-601-44, is currently undergoing preclinical assessment for its potential in addressing both Duchenne muscular dystrophy and myotonic dystrophy type 1. Furthermore, Entrada is actively developing EEV-PMO-CAG, also targeting myotonic dystrophy type 1. Incorporated in 2016, the firm was formerly known as CycloPorters, Inc., before officially changing its name to Entrada Therapeutics, Inc. in October 2017. The company maintains its corporate headquarters in Boston, Massachusetts.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Tops Revenue Estimates
Entrada Therapeutics (TRDA) delivered earnings and revenue surprises of +12.93% and +2.05%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Entrada Therapeutics Reports Second Quarter 2026 Financial Results
-- Company to report ELEVATE-44-201 data from Cohort 1 open-label period by year-end 2026 -- -- ELEVATE-44-201 Cohort 2 enrollment complete with data expected in Q1 2027 -- -- Company to report ELEVATE-45-201 Cohort 1 data in October 2026 -- -- ELEVATE-45-201 Cohort 2 dosing ongoing at the increased dose of 10 mg/kg with data expected in H1 2027 -- -- Vertex to report VX-670 Phase 1/2 data in people living with DM1 in H2 2026 -- BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc
Entrada Therapeutics Q2 EPS $(1.01) Beats $(1.09) Estimate, Sales $898.000K Beat $411.429K Estimate
Entrada Therapeutics (NASDAQ:TRDA) reported quarterly losses of $(1.01) per share which beat the analyst consensus estimate of $(1.09) by 7.34 percent. This is a 2.88 percent increase over losses of $(1.04) per share
Compugen (CGEN) Reports Q2 Loss, Misses Revenue Estimates
Compugen (CGEN) delivered earnings and revenue surprises of 0.00% and -3.63%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Wave Life Sciences (WVE) Reports Q2 Loss, Misses Revenue Estimates
Wave Life Sciences (WVE) delivered earnings and revenue surprises of -9.68% and -73.48%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?